Literature DB >> 10384246

Inhibitors of human immunodeficiency virus integrase.

Y Pommier1, N Neamati.   

Abstract

Integration of the viral DNA into a host cell chromosome is an essential step for HIV replication and maintenance of persistent infection. Two viral factors are essential for integration: the viral DNA termini (the att sites) and IN. Accruing knowledge of the IN structure, catalytic mechanisms, and interactions with other proteins can be used to design strategies to block integration. A large number of inhibitors have been identified that can be used as leads for the development of potent and selective anti-IN drugs with antiviral activity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10384246     DOI: 10.1016/s0065-3527(08)60310-3

Source DB:  PubMed          Journal:  Adv Virus Res        ISSN: 0065-3527            Impact factor:   9.937


  15 in total

Review 1.  Authentic HIV-1 integrase inhibitors.

Authors:  Chenzhong Liao; Christophe Marchand; Terrence R Burke; Yves Pommier; Marc C Nicklaus
Journal:  Future Med Chem       Date:  2010-07       Impact factor: 3.808

2.  Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy.

Authors:  J Mittler; P Essunger; G J Yuen; N Clendeninn; M Markowitz; A S Perelson
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

3.  Evidence that the retroviral DNA integration process triggers an ATR-dependent DNA damage response.

Authors:  René Daniel; Gary Kao; Konstantin Taganov; James G Greger; Olga Favorova; George Merkel; Tim J Yen; Richard A Katz; Anna Marie Skalka
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-04       Impact factor: 11.205

4.  Accumulation and intranuclear distribution of unintegrated human immunodeficiency virus type 1 DNA.

Authors:  P Bell; L J Montaner; G G Maul
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  Specific inhibition of human immunodeficiency virus type 1 (HIV-1) integration in cell culture: putative inhibitors of HIV-1 integrase.

Authors:  N Vandegraaff; R Kumar; H Hocking; T R Burke; J Mills; D Rhodes; C J Burrell; P Li
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

6.  Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations.

Authors:  Valery Fikkert; Bénédicte Van Maele; Jo Vercammen; Anke Hantson; Barbara Van Remoortel; Martine Michiels; Cristina Gurnari; Christophe Pannecouque; Marc De Maeyer; Yves Engelborghs; Erik De Clercq; Zeger Debyser; Myriam Witvrouw
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

7.  Styrylquinolines, integrase inhibitors acting prior to integration: a new mechanism of action for anti-integrase agents.

Authors:  Sabine Bonnenfant; Claire Marie Thomas; Claudio Vita; Frédéric Subra; Eric Deprez; Fatima Zouhiri; Didier Desmaële; Jean D'Angelo; Jean François Mouscadet; Hervé Leh
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 (HIV-1) integrase: resistance to diketo acid integrase inhibitors impairs HIV-1 replication and integration and confers cross-resistance to L-chicoric acid.

Authors:  Deborah J Lee; W E Robinson
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

9.  Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions.

Authors:  Evguenia S Svarovskaia; Rebekah Barr; Xuechun Zhang; Godwin C G Pais; Christophe Marchand; Yves Pommier; Terrence R Burke; Vinay K Pathak
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

10.  Inhibitors of strand transfer that prevent integration and inhibit human T-cell leukemia virus type 1 early replication.

Authors:  Samira Rabaaoui; Fatima Zouhiri; Agnès Lançon; Hervé Leh; Jean d'Angelo; Eric Wattel
Journal:  Antimicrob Agents Chemother       Date:  2008-03-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.